SecBot SecBot
6-K ·Filed Jun 22, 2026

LSBCF

LakeShore Biopharma Co., Ltd.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0001213900-26-070363
Notable filing: 6-K
Actionable Insight ▲ Bullish

Traders should monitor for the satisfaction of remaining closing conditions; if the merger consummates, LSBCF and LSBWF shares and warrants will cease trading on OTC Markets and be deregistered under the Exchange Act. Current holders may receive consideration per the merger terms, but no per-share price was disclosed in this filing.

DirectionBullish
Confidencehigh
Horizonweeks
Latest settled — T+5d
LSBCF ▲ 0.00% at T+5d
LONG call ✗ call lost 0.00% · α vs SPY +0.46% · entry $0.0670 → $0.0670
Next anchor: T+20d due 3mo ago
Entry = T+0 close
Jun 22, 2026
via day close
T+1d
0.00%
call 0.00% · α +1.45%
$0.0670
settled 4mo ago
T+5d
0.00%
call 0.00% · α +0.46%
$0.0670
settled 4mo ago
T+20d
Pending
due 3mo ago
T+60d
Pending
due 6w ago

Price Chart

Loading chart...

Executive Summary

LakeShore Biopharma shareholders voted overwhelmingly (86.2% of votes cast) to approve the merger agreement with Oceanpine Skyline Inc., moving the company one step closer to going private and delisting from OTC Markets. The high turnout (92.3% of outstanding shares) and approval margin signal strong shareholder support for the transaction.

Key Facts

  • Shareholders approved the merger agreement with 86.2% of votes cast at the extraordinary general meeting on June 19, 2026.
  • Approximately 92.3% of total outstanding ordinary shares were voted at the EGM.
  • Upon closing, the company will become privately held and its shares and warrants will be delisted from OTC Markets.
  • The merger agreement was originally dated November 4, 2025, and amended on April 29, 2026.
  • The parent entity is Oceanpine Skyline Inc., with Merger Sub as a wholly owned subsidiary.

Financial Impact

No deal price or consideration terms disclosed in the filing; merger consideration is not specified.

shares outstandingpublic float

Risk Factors

  • Merger may not close if conditions are not satisfied or waived; the filing notes risks including termination and financing availability.
  • Once closed, shares will be delisted and illiquid for public holders.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations
Analyst Consensus
80% bullish (5 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-070363
Document: ea029541301ex99-1.htm0001213900-26-070363
Document: 0001213900-26-070363-index-headers.html0001213900-26-070363
Document: 0001213900-26-070363-index.html0001213900-26-070363
Document: 0001213900-26-070363.txt0001213900-26-070363

US Market Status

Market Closed — Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 3, 2026